Portfolio Case
  • ·

    MBA from Zhongnan University of Economics and Law and an EMBA from Cheung Kong Graduate School of Business.

    ·

    A key member of the investment committee of China Pharmaceutical Innovation and Research Development Association, a member of Bayhelix Group.

    ·

    Selected as the ' Most Promising Investor in Shenzhen', 'China Finance Person of The Year 2019', 'China's Best New Venture Capital Manager in 2018'

    ·Efung has beenrated as “Shenzhen Top Ten Venture Capital Institutions“ and “Shenzhen Best Innovative Financial Institution” for many years.
    ·Over 19 years of experience in life science investment. 
    ·Has invested more than 20 domestic and oversea enterprises such as Mindray Medical ,  ChipScreen , Frontier Biotechnologies , Ascentage Pharma , Lifotronic , HaploX, Resverlogix, Centrexion Therapeutics, Apexigen and etc.


  • ·Co-founder of Huawei Technologies Co., Ltd.
    ·Over 40 years of experience in financial management; Over 20 years of experience in the communication industry.
    ·Served as the vice president of accounting, marketing, finance and economics in Huawei.
    ·

    Has participated in the Huawei's equity management,restructure, enterprise operations and many other projects.

    Joined Efung since 2012 as a managing partner. Responsible for risk management.


  • ·Xi 'an jiaotong university bachelor of business administration, cheung kong graduate school of business EMBA.
    ·Former Executive VP of a yacht club. Former CEO of Shenzhen Voyage Century Technology CO., LTD.
    ·As marketing directors, arranged for the openings of 3 top-class hotels in Shenzhen.


  • ·M.S. in chemical engineering at Northeastern University.
    ·Former associate at Sequoia Capital and over 5 years of business development experience.
    ·Former associate at Genzyme and Boheringer Ingelheim.  Years of experience in drug research and development. 


  • ·Bachelor of Economics at University of California San Diego.
    ·

    Former project manager of Guoxin Securities Asset Management Headquarters; responsible for the bank-certificate

    cooperation related projects including but not limited to entrusted loans, direct fund investment, trust income rights and other related businesses with a total scale of 30 billion RMB.


  • ·

    Ph.D. at Tulane University; Postdoctoral Fellow at University of Texas Medical center

    ·

    McKinsey alumni; Former co-founder of The Consulting Agency at TMC and Hulo Partners, LLC.

    ·

    Has reviewed over 500 life science companies in China and the U.S. Over 10 years of drug development research and investment experience.  Led investment cases such as Aridis Pharmaceuticals, Centrexion Therapeutics, Apexigen and etc. 


  • ·

    Doctor of Medicine at Beijing Medical University and Ph.D., at Japan Autonomous Medical University.

    ·

    Director of Chinese Disease Control and Prevention Center from 2004 to 2017.

    ·

    Distinguished Professor of Tsinghua University;Vice President of the Chinese Preventive Medicine Association, and Executive Director of the Chinese Medical Association. Director of the Institute of Liver Diseases of Beijing Medical University; Vice President of Beijing Medical University; 

    Deputy Director of the Department of Medicine at Peking University, and Deputy Director of Ministry of Science and Technology of China Biotechnology Development Center.

    ·

    Won the first prize of National Science and Technology Progress Award, the first prize of Science and Technology Progress of the Ministry of Health, the National Science and Technology Progress Special Award, and the National Outstanding Youth Science Fund.


  • ·Academician of the Chinese Academy of Sciences. 
    ·Served as the director of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences.
    ·Member of the Expert Group of the 863 Program; member of the Expert Group of National Natural Science Foundation.
    ·Has published more than 180 research papers on internationally renowned journals such as PNAS and JACS. Has participated in the compilation of 8 monographs and owned more than 80 patents invited to write 10 reviews on world renowed journals such as Nature Chemical Biology and Drug Discovery Today.


Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务